A study of LTP001 for healthy people and those with PAH
Part of Lungs & breathing clinical trials.
This study tests an investigational medicine called LTP001 for pulmonary arterial hypertension (PAH). Part A checks safety in healthy volunteers, and Part B tests if it helps people with PAH by improving blood flow in the lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a healthy adult (for Part A) or have a confirmed diagnosis of PAH (pulmonary arterial hypertension) (for Part B).
- If you have PAH, your lung artery pressure must be high (measured as PVR ≥400) and you must be on stable doses of standard PAH medicines.
- You need to be able to walk at least 150 meters but no more than 450 meters in 6 minutes (about 1-2 city blocks).
- Women who can get pregnant must use highly effective birth control; men must use condoms during the study and for 24 hours after the last dose.
- You must not have any significant heart or lung conditions (other than PAH) or allergies to the study drug ingredients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called IKT-001 for people with pulmonary arterial hypertension (PAH). It aims to see if IKT-001 helps improve exercise ability and other symptoms when added to current PAH therapies.
This trial tests an investigational drug called LAM-001 for people who have pulmonary hypertension (high blood pressure in the lungs) along with a type of lung disease called interstitial lung disease. The drug may help improve symptoms and daily function. This study will see if the drug is safe and helpful for this condition.
This study tests an investigational drug called IKT-001 for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. It is open-label, meaning everyone knows they are getting the drug, and it is for people who have already been in a previous study of IKT-001.
This trial tests a new medication called REGN13335 for people with pulmonary arterial hypertension (PAH). It aims to see if the drug can improve symptoms and function compared to standard care alone.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This study looks at how the cells lining your blood vessels and the pressure in your lungs affect pulmonary arterial hypertension (PAH). It tests a new drug called XBD173 to see if it can help improve your condition.
Hear when a new Healthy Volunteers, Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.